Zhou J, Sun X Y, Stenzel D J, Frazer I H
Lions Human Immunology Laboratory, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Virology. 1991 Nov;185(1):251-7. doi: 10.1016/0042-6822(91)90772-4.
A recombinant vaccinia virus termed pLC201VV was designed to coexpress the L1 and L2 late genes of human papillomavirus type 16 (HPV16). Synthesis of the L1 and L2 proteins occurred in cells infected with pLC201VV, and 40-nm virus-like particles with a density of 1.31 g/ml were produced in the nuclei of cells synthesizing both L1 and L2, but not in cells synthesizing either protein alone. Virus-like particles were partially purified from infected cells by sucrose gradient sedimentation and shown to consist of capsomeres similar to HPV and contain glycosylated L1 viral capsid protein. The production of HPV-like particles using recombinant vaccinia virus should be useful for biochemical studies and could provide a safe source of material for the development of a vaccine.
一种名为pLC201VV的重组痘苗病毒被设计用于共表达人乳头瘤病毒16型（HPV16）的L1和L2晚期基因。L1和L2蛋白的合成发生在感染pLC201VV的细胞中，在同时合成L1和L2的细胞的细胞核中产生了密度为1.31 g/ml的40纳米病毒样颗粒，但在仅合成其中一种蛋白的细胞中未产生。病毒样颗粒通过蔗糖梯度沉降从感染细胞中部分纯化，结果显示其由类似于HPV的衣壳粒组成，并含有糖基化的L1病毒衣壳蛋白。利用重组痘苗病毒生产HPV样颗粒将有助于生化研究，并可为疫苗开发提供安全的材料来源。
